- Bausch Health stock (TSX:BHC) is poised to soar after entering into a $600 million financing with KKR
- The pharmaceutical company will use the additional liquidity for general corporate purposes over a five-year term
- Bausch Health is a globally diversified pharmaceutical company
- Bausch Health stock (TSX:BHC) last traded at $10.29 per share
Bausch Health stock (TSX:BHC) is poised to soar after entering into a $600 million financing with KKR.
KKR is a legendary global investment firm focused on alternative asset management, capital markets and insurance solutions. Its investments are concentrated in private equity, credit, real assets and hedge funds.
Bausch Health will use the proceeds for general corporate purposes over a five-year term.
Bausch Receivables Funding LP, an Ontario limited partnership and wholly owned subsidiary of Bausch Health, entered into the non-recourse financing facility with KKR and its credit funds and accounts.
The facility is collateralized by accounts receivables from a wholly owned subsidiary of Bausch Health.
Houlihan Lokey acted as Bausch Health’s financial advisor while Finacity Corporation acted as administrator.
Bausch Health is a globally diversified pharmaceutical company developing, manufacturing and marketing products in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health.
Bausch Health stock (TSX:BHC) last traded at $10.29 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Bausch Health stock forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.